Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinostamustine in relapsed or refractory small cell lung cancer
2020-004246-11Phase 2Completed
- Sponsor
- Mundipharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tinostamustine in small cell lung cancer (SCLC), sponsored by Mundipharma. Primary endpoint: Objective response rate plus durable stable disease rate. Started May 2021; status: completed.
02
Drugs
tinostamustine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-004246-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004246-11.